Walleye Capital LLC Vir Biotechnology, Inc. Transaction History

Walleye Capital LLC

$46.2 Billion
Q3 2024

A detailed history of Walleye Capital LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 200 shares of VIR stock, worth $1,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Holding current value

$1,480

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.26 - $10.7 $172,613 - $254,403	23,776 New	23,776 $178,000
Q1 2024 May 15, 2024	SELL	$8.6 - $11.9 $96,044 - $132,899	-11,168 Reduced 6.08%	172,656 $1.75 Million
Q4 2023 Feb 14, 2024	SELL	$7.76 - $10.29 $3.06 Million - $4.06 Million	-394,711 Reduced 68.23%	183,824 $1.85 Million
Q3 2023 Nov 14, 2023	SELL	$9.14 - $24.62 $2.6 Million - $7.01 Million	-284,845 Reduced 32.99%	578,535 $5.42 Million
Q2 2023 Aug 14, 2023	BUY	$23.2 - $27.29 $20 Million - $23.6 Million	863,380 New	863,380 $21.2 Million
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $108,069 - $204,051	-5,100 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$30.97 - $54.03 $157,947 - $275,553	5,100 New	5,100 $213,000

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

Sb Investment Advisers (Uk) LTD London, X0

16.7M
Shares

$123 Million
1.03% of portfolio
Black Rock Inc. New York, NY

16.4M
Shares

$122 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$97.2 Million
0.0% of portfolio
State Street Corp Boston, MA

5.63M
Shares

$41.6 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

3.57M
Shares

$26.4 Million
0.63% of portfolio

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account